RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer

被引：0
作者：
Chunyue Wang
Zhenlong Zhang
Yulan Sun
Song Wang
Mengmeng Wu
Qiuxiang Ou
Yang Xu
Zhiming Chen
Yang Shao
Hong Liu
Peifeng Hou
机构：
[1] Xiamen University,Department of Medical Oncology, Xiamen Key Laboratory of Antitumor Drug Transformation Research, The First Affiliated Hospital of Xiamen University, School of Medicine
[2] Shengli Clinical Medical College of Fujian Medical University,Department of Thoracic Surgery
[3] Fujian Provincial Hospital,Department of Internal Medicine Division
[4] Shandong Cancer Hospital Affiliated to Shandong First Medical University,Department of Radiation Oncology
[5] Geneseeq Research Institute,Department of Medical Oncology
[6] Nanjing Geneseeq Technology Inc.,undefined
[7] Affiliated Hospital of Nantong University,undefined
[8] Qilu Hospital of Shandong University,undefined
[9] Fujian Medical University Union Hospital,undefined
来源：
Journal of Translational Medicine | / 20卷
关键词：
rearrangement; NSCLC; EGFR-TKI; Noncanonical ; fusion;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer
    Camidge, D. Ross
    Davies, Kurtis D.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (11) : 855 - +
  • [42] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Elena María Martínez-Navarro
    Joseba Rebollo
    Ramón González-Manzano
    Manuel Sureda
    Elena Evgenyeva
    Belén Valenzuela
    Francisco José Fernández
    Jerónimo Forteza
    Antonio Brugarolas
    Clinical and Translational Oncology, 2011, 13 : 812 - 818
  • [43] Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    Koinis, F.
    Voutsina, A.
    Kalikaki, A.
    Koutsopoulos, A.
    Lagoudaki, E.
    Tsakalaki, E.
    Dermitzaki, E. K.
    Kontopodis, E.
    Pallis, A. G.
    Georgoulias, V.
    Kotsakis, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2018, 20 (02) : 140 - 149
  • [44] Long-term clinical benefit from salvage EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer patients with EGFR wild-type tumors
    F. Koinis
    A. Voutsina
    A. Kalikaki
    A. Koutsopoulos
    E. Lagoudaki
    E. Tsakalaki
    E. K. Dermitzaki
    E. Kontopodis
    A. G. Pallis
    V. Georgoulias
    A. Kotsakis
    Clinical and Translational Oncology, 2018, 20 : 140 - 149
  • [45] Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)
    Maria Martinez-Navarro, Elena
    Rebollo, Joseba
    Gonzalez-Manzano, Ramon
    Sureda, Manuel
    Evgenyeva, Elena
    Valenzuela, Belen
    Jose Fernandez, Francisco
    Forteza, Jeronimo
    Brugarolas, Antonio
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2011, 13 (11) : 812 - 818
  • [46] Activating MET Tyrosine Kinase Domain Mutations as de Novo Oncogenic Drivers in Non-small Cell Lung Cancer
    Nakazawa, S.
    Pecci, F.
    Ricciuti, B.
    Harada, G.
    Lee, J. K.
    Alessi, J. V.
    Barrichello, A. P. C.
    Vaz, V. R.
    Lamberti, G.
    Di Federico, A.
    Gandhi, M. M.
    Gazgalis, D.
    Feng, W. W.
    Jiang, J.
    Chen, M.
    Lee, E.
    Haradon, D.
    Smokovich, A.
    Voligny, E.
    Nguyen, T.
    Goel, V.
    Zimmerman, Z.
    Wang, X.
    Bahcall, M.
    Heist, R.
    Iqbal, S.
    Che, J.
    Schrock, A. B.
    Drilon, A.
    Janne, P. A.
    Awad, M. M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S88 - S89
  • [47] Concurrent Thoracic Radiotherapy and Tyrosine Kinase Inhibitors for Wild-Type EGFR Patients with Locally Advanced Non-Small Cell Lung Cancer
    Zheng, Zhi S.
    Xia, Bing
    Xie, Rui F.
    Li, Xia D.
    Zhu, Jue
    Wu, Shi X.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S548 - S548
  • [48] Altered splicing of ATG16-L1 mediates acquired resistance to tyrosine kinase inhibitors of EGFR by blocking autophagy in non-small cell lung cancer
    Hatat, Anne-Sophie
    Benoit-Pilven, Clara
    Pucciarelli, Amelie
    de Fraipont, Florence
    Lamothe, Lucie
    Perron, Pascal
    Rey, Amandine
    Levra, Matteo Giaj
    Toffart, Anne-Claire
    Auboeuf, Didier
    Eymin, Beatrice
    Gazzeri, Sylvie
    MOLECULAR ONCOLOGY, 2022, 16 (19) : 3490 - 3508
  • [49] A comparison of ARMS and direct sequencing for EGFR mutation analysis and Tyrosine Kinase Inhibitors treatment prediction in body fluid samples of Non-Small-Cell Lung Cancer patients
    Yi Liu
    Bing Liu
    Xiao-Yan Li
    Jian-Jie Li
    Hai-Feng Qin
    Chuan-Hao Tang
    Wan-Feng Guo
    Hai-Xu Hu
    Sha Li
    Cui-Jing Chen
    Bing Liu
    Hong-Jun Gao
    Xiao-Qing Liu
    Journal of Experimental & Clinical Cancer Research, 30
  • [50] Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
    De Luca, A.
    Normanno, N.
    CURRENT DRUG TARGETS, 2010, 11 (07) : 851 - 864
12345